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Evaluating cost eﬀectiveness of interventions for aging in place is essential for adoption in service settings. We present the
cost eﬀectiveness of Advancing Better Living for Elders (ABLE), previously shown in a randomized trial to reduce functional
diﬃculties and mortality in 319 community-dwelling elders. ABLE involved occupational and physical therapy sessions and
home modifications to address client-identified functional diﬃculties, performance goals, and home safety. Incremental cost-
eﬀectiveness ratio (ICER), expressed as additional cost to bring about one additional year of life, was calculated. Two models were
then developed to account for potential cost diﬀerences in implementing ABLE. Probabilistic sensitivity analyses were conducted
to account for variations in model parameters. By two years, there were 30 deaths (9: ABLE; 21: control). Additional costs for 1
additional year of life was $13,179 for Model 1 and $14,800 for Model 2. Investment in ABLE may be worthwhile depending on
society’s willingness to pay.
1. Introduction
The primary health problems confronting older adults are
chronic and can aﬀect their ability to carry out everyday
self-care [1]. Functional diﬃculties significantly compromise
quality of life and are associated with increased frailty,
depression, nursing home placement, and mortality [2, 3].
Numerous interventions have been tested in randomized
trials that may help older adults with late-life disability age
in place at home [4, 5]. Nevertheless, research shows that
functionally vulnerable elders continue to receive inadequate
care [6–9]. To reverse this situation and enhance wide-scale
adoption and implementation of proven programs in service
settings, economic evaluations of promising interventions
must be conducted [10, 11].
Only a few home-based interventions targeting older
adults with late-life disability have been evaluated for
cost eﬀectiveness with studies demonstrating cost savings.
However, most of these studies have involved European
programs or preventive approaches not specifically designed
to improve function or reduce mortality in at-risk vulnerable
older adults living at home in the USA [12–14].
One promising home intervention tested in the USA
is Advancing Better Living for Elders (ABLE) [15, 16].
ABLE was previously tested in a two-group randomized
parallel trial with 319 older adults who had diﬃculties
with instrumental or daily activities of living. ABLE was
designed to address client-identified functional diﬃculties,
performance challenges at home, and home safety concerns.
Compared to a no-treatment control group, ABLE was
shown to reduce functional diﬃculties and enhance home
safety and self-eﬃcacy to manage daily functional challenges
at 6 and 12 months. Moreover, ABLE reduced mortality at 12
and 24 months from study entry [15–18].
Given ABLE’s promising outcomes and to extend an
understanding of the benefits of this intervention, we con-
ducted an economic analysis post hoc. The purpose of this
study is to estimate the cost eﬀectiveness of implementing
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ABLE from the perspective of a homecare agency. Only
costs associated with the implementation of ABLE were
considered and two cost scenarios were developed to account
for potential cost diﬀerences in implementing ABLE. These
analyses used an incremental cost-eﬀectiveness ratio (ICER)
with the primary outcome measure of life years saved (LYS)
over two years.
2. Methods
2.1. Study Design and Sample. The original ABLE trial
was conducted between 2000 and 2003 with survivorship
followed out to December 2005. As previously reported
[15], trial participants were 70 years or older, cognitively
intact, and living at home with functional diﬃculties.
Participants were recruited through service agencies and
media announcements. Of the 319 participants enrolled, 159
were randomized to ABLE and 160 to a no-treatment (usual
care) control group. For this study, baseline interview data
was used to characterize the sample. Data from the National
Death Index (NDI) records were used to determine length of
time of survivorship up to December 31, 2005.
2.2. Intervention. ABLE participants received five occupa-
tional therapy (OT) contacts (four 1.5-hour visits and one
brief telephone contact) and one 1.5-hour physical therapy
(PT) home visit over the first six months. OTs identified and
prioritized functional diﬃculties, and provided strategies
to modify the environment, enhance safety, and minimize
performance diﬃculties. OTs identified home modification
needs and, with client approval, coordinated product order-
ing, delivery, and implementation through the Housing
Department of the Philadelphia Corporation for Aging (the
region’s area agency on aging). PTs provided balance and
muscle strengthening exercises, fall recovery techniques, and
referral for additional therapy if necessary. In the following
six months (maintenance phase), participants received three
brief OT telephone calls to reinforce strategy use. A final OT
home visit provided closure.
Control group participants did not receive intervention
contact. At study completion (12-month interview), partici-
pants received a home safety booklet free to the public.
2.3. Cost-Eﬀectiveness Model. A decision analytic model was
constructed for the cost-eﬀectiveness analyses using TreeAge
Pro 2009 statistical software. Two models were constructed
to account for variation in cost estimates. Model 1 (base
case) reports on estimated costs of delivering ABLE in a
home care agency. Model 2 (base case + 10%) accounts for
a potential variation in the cost of delivering ABLE in a real
world setting.
2.4. Cost. Costs were calculated based on recommendations
of the US Public Health Service Panel on Cost-Eﬀectiveness
andmajor peer-reviewed journals [1, 19–23]. All costs inputs
are reported in Table 2; costs were captured in 2003 dollars to
reflect when the original data was collected and then adjusted
to 2010 dollars. Costs of the intervention reflected five
direct categories; OT/PT home and telephone sessions, staﬀ
training, intervention materials, therapist travel, and home
modifications (ordering, installing, and quality control).
Time spent by OTs delivering the intervention was
estimated to be 1.5 hours per home visit and 15 minutes
per telephone call. This estimate was derived from reviewing
the study design and post hoc interviews with OT study
interventionists. Per-hour pay for OTs was calculated using
national average rates ($28) for OTs with one to four years
experience [24], with an additional 25% added to account for
fringe benefits. Also, 15 minutes were estimated to account
for preparation and documentation for each session.
We estimated the time spent by the PT conducting the
intervention (1.5 hr/home visit) based on a review of the
study design and post hoc interviews with interventionists.
Per-hour pay for the PT was calculated using the national
average rate of $31 for PTs with one to four years experience;
an additional 25% was assumed for fringe benefits [24].
An additional 15 minutes were estimated to account for
preparation and documentation following the session based
on therapist records.
Staﬀ training time for seven OTs and one PT was 16
hours and involved instruction in the study protocol. Similar
assumptions for hourly wage rates as above were applied.
Cost of training was estimated on a per-participant basis.
To estimate cost on a per-participant basis we calculated the
total cost of training and divided this number by the number
of study participants in the intervention group.
There were two types of material costs: (1) those used
by interventionists ($5) and (2) education print materials
provided to participants ($10). Total cost of materials per
participant was estimated to be $15.
Interventionist travel expenses to and from participant
homes were calculated based on an average of a 20 mile
radius round trip per visit, reimbursed at the government
rate of $.51 a mile [25].
Home modification (e.g., grab bars and raised toilet
seats) costs included ordering, purchasing, installing, and
assuring quality.
2.5. Outcome Measure—Life Years Saved (LYS). For the cost-
eﬀectiveness analysis, we used LYS over two years as the
primary outcome measure. The survival benefit of ABLE
compared to control has been described elsewhere [18].
Briefly, to determine survival benefit, the number of days
to death was calculated from the baseline interview until
date of death or December 31, 2005 using data from the
National Death Index. Kaplan-Meier method was used to
analyze survival rate at two years from date of study entry
[18]. Diﬀerence in area under the Kaplan-Meier curve was
then used to estimate LYS.
2.6. Discounting. Because the eﬀects of the ABLE interven-
tion occurred over a period of two years, it is necessary
to account for the time delay of the benefit as it is more
advantageous to receive a benefit earlier rather than later [21,
22]. To adjust for the time delay of a benefit, we discounted
our outcome measure, life years saved, by a factor of 3%.
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Table 1: Background characteristics.
Characteristic
Control
(n =159)
Experimental
(n = 160)
Total
(N = 319)
P
Mean Age (SD) 78.5 (5.7) 79.5 (6.1) 79.0 (5.9) .158
Race (%) .387
White 52.2 53.1 52.7
African 45.9 45.0 45.5
American
Hispanic 0.0 1.3 0.6
Other 1.9 0.6 1.2
Gender (%) .751
Male 18.9 17.5 18.2
Female 81.1 82.5 81.8
Living arrangement (%) .462
Alone 59.7 63.8 61.8
With others 40.3 36.3 38.2
Education (%) .916
<High school 37.7 35.6 36.7
High school 30.2 31.9 31.0
>High school 32.1 32.5 32.3
Mean number of health conditions (SD) 7.1 (2.8) 6.7 (2.7) 6.9 (2.7) .295
MMSE 27.0 (1.8) 26.8 (1.8) 26.9 (1.8) .346
MMSE: Mini-mental status examination.
Costs were not discounted because they were incurred only
during the first year of the study.
2.7. Incremental Cost-Eﬀectiveness Ratio (ICER). The ICER
was calculated by taking the diﬀerence in cost between the
intervention and the control group divided by the diﬀerence
in survival benefit between treatment and control groups
[22, 23]. The ICER therefore represents the additional costs
to bring about one life year saved from the intervention
compared to usual care.
2.8. Sensitivity Analyses. In order to account for uncertain-
ties in our model, probabilistic sensitivity analyses (PSA)
were performed on both Models 1 and 2. To conduct a
PSA, each variable in the model is assigned a mean and
distribution around its mean. TreeAge Pro 2009 was used
to calculate the PSA. To derive the results of the analysis,
the mean incremental cost and eﬀect, TreeAge Pro 2009
runs 1000 microsimulations. During each simulation, the
computer uses the distribution around each variable to
generate average costs and eﬀects. Based on the average
costs and eﬀects over 1000 microsimulations, the computer
then estimates the mean incremental cost and eﬀect. Results
from the PSA are presented as an acceptability curve. The
acceptability curve graphically illustrates the probability
of the intervention being cost eﬀective over a range of
willingness-to-pay values.
To be consistent with the methodology of the PSA, each
variable in Models 1 and 2 was assigned a distribution of
values based on the standard deviations calculated during the
initial study. However, for some variables (e.g., occupational
therapist time on phone), data was not uniformly available
from the clinical trial. For these cases, we derived estimations
from consulting with research staﬀ or the literature.
3. Results
3.1. Study Participants. Characteristics of the study pop-
ulation have been presented elsewhere [15]. Briefly, there
were no large or statistically significant diﬀerences between
intervention and control group participants at baseline on
demographic and health variables (Table 1).
3.2. Cost. Total cost of ABLE per participant was $942
(Table 2). Cost for the no-treatment control group was $0
given that no program treatment was received. In Model 2
(base case + 10%), cost of ABLE was $1,036.
3.3. Outcome Measure—Life Years Saved. By two years, 30
study participants had died; 9 deaths in the intervention and
21 deaths in the control group. Based on previously pub-
lished Kaplan-Meier survival analysis [18], the intervention
group (n = 160) had a survival rate of 94% (n = 9 deaths)
reflecting a mortality rate of 6%; this is in comparison to the
control group (n = 159) which had a survival rate of 87%
or a mortality rate of 13% (n = 21 deaths; P = .02). The
diﬀerence between mortality rates represents the additional
survival benefit of ABLE.
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Table 2: Cost categories for ABLE program.
Cost categories Cost (range)
(1) Time spent with ABLE
participants
OT preparation $57 ($44–$67)
OT contact $299 ($239–$359)
PT preparation $10 ($8–$12)
PT contact $58 ($46–$69)
(2) Training
OT/PT $5 ($4–$6)
(3) Materials
For OT/PT $5 ($4–$6)
For participants $10 ($8–$12)
(4) Travel
Mileage $61 ($49–$73)
(5) Home modifications
Modifications $439 ($351–$527)
Total average cost per person $942
3.4. ICER and Sensitivity Analysis of ICER Estimate. Under
the assumptions of Model 1, the ICER (cost per one addi-
tional year of life) was $13,179 and under the assumptions of
Model 2, the ICER is $14,800.
Figure 1 details the acceptability curve for Models 1
and 2. Based on the acceptability curve and under the
assumptions of Model 1, ABLE is cost eﬀective greater than
50% of the time as long as a purchaser is willing to pay
more than $13,000 for one additional year of life. Under the
assumptions of Model 2, ABLE is cost eﬀective greater then
50% of the time as long as the purchaser is willing to pay
more than $14,800 for one additional year of life.
4. Discussion
To our knowledge, this is one of the first cost-eﬀectiveness
analyses of a home-based intervention tested in the USA
which reduced functional diﬃculties and mortality risk in
vulnerable older adults. The original ABLE trial did not
include cost as a study aim and thus the cost analyses pre-
sented here were post hoc and hence necessarily exploratory.
Our study demonstrates, however, the value of conducting
cost analyses even post hoc to derive preliminary economic
conditions of eﬀectiveness and enhance the implementation
potential of existing proven programs for vulnerable older
adults. There are two key findings from this study. First,
ABLE’s cost eﬀectiveness is within an acceptable range of
willingness to pay (WTP) values identified in previous
related studies, although research is very limited in this area.
Second, the cost of ABLE is reasonable and compares favor-
ably to other nonpharmacologic, home-based interventions
for older adults.
Traditionally, cost-eﬀectiveness analyses use quality-
adjusted life years (QALYs) as the primary outcome measure
and apply a WTP threshold of $50,000 per quality-adjusted
life (QALY). However, in ABLE, QALYs were not captured
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in the original trial, a potential limitation of this economic
study. Thus, we were unable to use this standard metric to
evaluate cost eﬀectiveness. To aid in the interpretation of our
findings and compensate for the lack of QALY outcomes,
we searched the literature for studies which evaluated WTP
for interventions that decrease morality. By searching for
established WTP values, we sought to determine the value
of one additional year of life, as reported in the literature.
ApplyingWTP values published previously to ABLE provides
a preliminary contextual basis for understanding our derived
ICER estimates.
Our search yielded only two studies that can provide
some insight as to WTP for ABLE [26, 27]. Johannesson
and Johansson [26] estimated the WTP ($400–$1500) for
a one-year increase in life expectancy of a hypothetical
intervention. Taking the average of this range ($950) and
adjusting for inflation, we arrived at an estimated WTP
of $1,299/year. Applying Johannesson and Johansson WTP
estimate to the acceptability curve generated in our study,
ABLE would not be cost eﬀective under either Model 1 or
Model 2 [26].
However, Johannesson and JohanssonWTP estimate was
low compared to other published studies [26, 28]. One
possible explanation for the low estimate is that Johannesson
and Johansson surveyed a Swedish population and, thus,
their preferences may not be the same as a US population. In
addition, the population surveyed was younger (<69) than
the ABLE population (mean age 79).
In another study, Johnson et al. evaluated WTP by
asking respondents how much they would be WTP for
one additional year of life based on six quality of life
scenarios (no physical limitations and no social limitations,
some physical limitations and no social limitations, some
physical limitations and some social limitations, home
bound, need help, and in hospital) [27]. The authors found
that individuals were willing to pay the most for the scenario
in which they had no physical or social limitations. The ABLE
population could be described as having some physical and
social limitations [15, 16]. Johnson et al. found the WTP
interval (after adjusting for inflation and currency exchange
rates) for this subgroup to be between $1,754 and 17,556. If
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we were to apply the upper range (>$14,800) of the Johnson
et al. WTP estimates to our acceptability curve (Figure 1),
ABLE would be considered cost eﬀective greater than 50%
of the time.
Although the WTP data that is applicable to ABLE is
limited, these two studies provide some basis for contex-
tualizing the ABLE ICER estimate. While it is diﬃcult to
make generalizations about the cost eﬀectiveness of ABLE
given limited WTP data, utilizing the acceptability curve
(Figure 1), an individual decision maker can determine the
probability of ABLE being cost eﬀective given their own
WTP. More importantly, the dearth of WTP data indicates
the need for future studies to collect and report on such
values for older adults with late-life disability.
The cost of implementing ABLE relative to similar
programs is also diﬃcult to evaluate as there are limited
studies on the cost of similar novel home-based interven-
tions. An OT program for well elderly reported average
program costs of $548 per participant with cost per QALY
for the intervention estimated at $10,666 [12]. While average
costs for ABLE were $400 higher, the diﬀerence is chiefly
due to costs associated with specialized equipment ($439)
important to vulnerable elders or those aging at home with
functional diﬃculties.
ABLE also compares favorably to an OT dementia care-
giver intervention tested in The Netherlands [13]. Interven-
tion costs per patient in The Netherlands study were $1,738
(USD), and the intervention was found to be successful only
36% of the time.
Finally, ABLE compares favorably to The Geriatric Re-
sources for Assessment and Care of Elders model (GRACE)
[11]. GRACE is 2-year home based care management
intervention designed to improve quality of care and reduce
acute care. The mean cost of GRACE per patient per year
was $1,000 [29], almost identical to ABLE. However, unlike
in ABLE, there was no statistical diﬀerence in mortality rate
between the intervention and control arms of the GRACE
study.
As this is a post hoc study, we were unable to derive real-
time costs, a study limitation. Our method for estimating the
cost of delivering ABLE was based on a review of the study
protocol and interviews with intervention staﬀ. Although
we were thorough in our analyses, we believe that our cost
estimate may in fact overestimate the cost of ABLE because
it does not take into account potential cost savings. For
example, those in the ABLE group benefited from a decrease
in functional diﬃculties and mortality. Thus, there is a
strong possibility that those in the ABLE group compared
to the control group actually used less health care services.
Unfortunately, the original data does not lend itself to an
estimate of health care utilization, a significant limitation.
Several other study limitations should also be noted.
First, we were unable to conduct our analyses from a societal
perspective and, thus, some may view this as major study
limitation. Secondly, traditional cost-eﬀectiveness analyses
use QALYs as the primary outcome measure instead of
QALYs, we used life years saved. Although it would have been
ideal to include QALYs in this analysis, as stated above, the
original parent trial did not capture this data.
In conclusion, although there are limitations to all cost-
eﬀectiveness analyses, these studies are at the forefront of
a growing trend in health economics to quantify benefits
of proven programs from which to make judgments as to
what should be translated into real-world services. With
the aging of the population, it is increasingly important
to measure cost eﬀectiveness of programs that help older
adults remain independent in their homes. To advance
services and policies that support aging in place, economic
analyses of promising programs are important. Few existing
proven programs for functionally vulnerable older adults
have included cost analyses prospectively. However, we show
in this study that it is possible to evaluate the cost of a
proven program post hoc, although admittedly there are
limitations to a retrospective approach and it is preferable
to conduct such analyses prospectively. Nevertheless, our
approach oﬀers a preliminary understanding of the costs
of a highly eﬀective program. The cost of ABLE can be
considered low in view of the high cost of medical and
drug therapies. Also, the results from the cost-eﬀectiveness
analyses of ABLE show that the additional cost to bring about
one additional year of life to older adults living at home with
functional diﬃculties compares somewhat favorably to the
very few studies conducted in this area. Future studies of
ABLE and other related programs will need to be conducted
in which treatment eﬀects are measured over a longer
period of time and cost analyses are considered a priori to
study implementation so as to capture cost from a societal
perspective. Finally, future studies that use nontraditional
outcome measures need to place ICER estimates in real
world context by evaluating an individual and a society’s
willingness to pay for such benefits.
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